

REMARKS

1. *Status of claims*

After entry of the above amendment, claims 1, 3-4, 6-10, and 12-19 are pending.

2. *Support for amendment*

The amendment to claims 1 and 10 finds support in the specification at p. 8, lines 14-15 and in Figures 2, 7, and 8. The amendment to claim 8 is intended to aid in the definition of the invention as recited by that claim. No new matter has been added by this amendment.

3. *Further remarks*

Erlanger, U.S. Pat. No. 6,593,137 (“Erlanger”) teaches administering to a patient a bispecific antibody, where one end is a fullerene antibody and the other is a tumor-specific monoclonal antibody, followed by administration of a radioisotope-containing water-soluble fullerene, which binds to the fullerene-antibody end of the bispecific antibody (col. 27, lines 1-12). The present claims differ from Erlanger at least by reciting a composition containing an antibody which recognizes an antigen associated with a disease and is covalently linked to a fullerene or carbon nanotube. At the passage above, Erlanger recites a composition containing an antibody which recognizes an antigen associated with a disease (the tumor-specific monoclonal antibody) but is not covalently linked to a fullerene.

Other references of record include Williams *et al.*, *Int. J. Radiat. Oncol. Biol. Phys.*, 1990 Sep;19(3):633-42 (“Williams”) and Østensen *et al.*, U.S. Pat. No. 6,375,931 (“Østensen”). Williams discloses radiolabeled antibodies specific against tumor antigens and methods of using the radiolabeled antibodies to treat tumors. Østensen discloses compositions containing gases,

therapeutic drugs, and fullerenes and methods of targeting them to specific areas by injection or by disrupting the fullerenes to release the therapeutic drugs. No combination of the references teaches or suggests a composition containing an antibody which recognizes an antigen associated with a disease and is covalently linked to a fullerene or carbon nanotube.

Should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Director is authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4451.003200RE.

Respectfully submitted,

WILLIAMS, MORGAN & AMERSON, P.C.
CUSTOMER NO. 23720

March 7, 2007

/Raymund F. Eich/
Raymund F. Eich, Ph.D.
Reg. No. 42,508

10333 Richmond, Suite 1100
Houston, Texas 77042
(713) 934-4065
(713) 934-7011 (fax)

AGENT FOR APPLICANTS